14:44 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest stimulating cholesterol efflux in phagocytes by promoting LXR expression could help treat MS. In a mouse model of lysolecithin-induced MS, cholesterol accumulation in the membranes of lesion-infiltrating phagocytes was...
07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Liver X receptor (LXR)

Cardiovascular disease INDICATION: Atherosclerosis Mouse and patient sample studies suggest promoting LXR expression with 2-hydroxypropyl-β-cyclodextrin (HPBCD) could help treat atherosclerosis. In primary mouse macrophages and carotid atherosclerotic plaque samples from patients, HPBCD increased expression of LXR target...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

ALX-101: Phase IIa started

Alexar began a double-blind, placebo-controlled, U.S. Phase IIa trial of 2 dose levels of ALX-101 topical gel in 72 patients. Alexar Therapeutics Inc., Malvern, Pa.   Product: ALX-101   Business: Dermatology   Molecular target: Liver X...